Literature DB >> 34906210

Lipid A-Ara4N as an alternate pathway for (colistin) resistance in Klebsiella pneumonia isolates in Pakistan.

Kiran Iqbal Masood1, Seema Umar1, Zahra Hasan1, Joveria Farooqi1, Safina Abdul Razzak1, Nazish Jabeen1, Jason Rao2, Sadia Shakoor1, Rumina Hasan3,4.   

Abstract

OBJECTIVES: This study aimed to explore mechanism of colistin resistance amongst Klebsiella pneumoniae isolates through plasmid mediated mcr-1 gene in Pakistan. Carbapenem and Colistin resistant K. pneumoniae isolates (n  = 34) stored at - 80 °C as part of the Aga Khan University Clinical Laboratory strain bank were randomly selected and subjected to mcr-1 gene PCR. To investigate mechanisms of resistance, other than plasmid mediated mcr-1 gene, whole genome sequencing was performed on 8 clinical isolates, including 6 with colistin resistance (MIC  >  4 μg/ml) and 2 with intermediate resistance to colistin (MIC  >  2 μg/ml).
RESULTS: RT-PCR conducted revealed absence of mcr-1 gene in all isolates tested. Whole genome sequencing results revealed modifications in Lipid A-Ara4N pathway. Modifications in Lipid A-Ara4N pathway were detected in ArnA_ DH/FT, UgdH, ArnC and ArnT genes. Mutation in ArnA_ DH/FT gene were detected in S3, S5, S6 and S7 isolates. UgdH gene modifications were found in all isolates except S3, mutations in ArnC were present in all except S1, S2 and S8 and ArnT were detected in all except S4 and S7. In the absence of known mutations linked with colistin resistance, lipid pathway modifications may possibly explain the phenotype resistance to colistin, but this needs further exploration.
© 2021. The Author(s).

Entities:  

Keywords:  Antimicrobial drug resistance; Klebsiella pneumonia; mcr-1 gene

Mesh:

Substances:

Year:  2021        PMID: 34906210      PMCID: PMC8670247          DOI: 10.1186/s13104-021-05867-3

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

Beta-lactams have always been the backbone of antibiotic regimens targeting infections with Enterobacteriaceae including K. pneumoniae [1]. With the increase in resistance to these agents [1, 2] there is interest in using colistin (polymyxin E) for treating such infections. Colistin targets lipopolysaccharides (LPS) and phospholipids present in the outer cell membrane of Gram-negative bacteria, and competitively displaces divalent cations from the phosphate groups of membrane lipids leading to pore formation and disruption of the outer cell membrane, leakage of cytoplasmic contents, and bacterial death. A worldwide increase in resistance to colistin has been reported globally [3, 4]. Such resistance can either be acquired, or occur as a result of intrinsic factors [5]. Mobile colistin resistance (mcr) genes acquired through plasmids were first reported in China in 2015 [6]. The first colistin resistant E. coli with mcr-1 was reported from Pakistan in 2017 [7]. The intrinsic factors contributing to colistin resistance mainly involves the modification of the LPS moiety by the addition of positively charged molecules L-Ara4-N and PEtN [8]. The addition of positively-charged molecules result in the decrease of negative charge in the outer membrane thus reducing its affinity to interact with cationic antibiotics including colistin [9]. Alterations in LPS most commonly occur due to mutations in bacterial genes including mgrB, phoP/phoQ, pmrA, pmrB, pmrC, and crrABC [10-12].Increasing colistin resistance amongst K. pneumoniae emphasizes the need to understand mechanisms contributing to such resistance. This study is therefore aimed to explore mechanism of colistin resistance amongst K. pneumoniae isolates from Pakistan, and to study the role of plasmid-mediated (mcr-1 gene) and chromosomal factors contributing to such resistance.

Main text

Methods

Study subjects

The clinical isolates (n  = 34) were randomly selected from the Aga Khan University Clinical Laboratory strain bank stored at − 80 °C and used anonymously. The source of the selected strains included sputum (n:1), tracheal aspirates (n:9), blood (n:9), urine (n:8), tissue (n:4), pus (n:2) and cerebrospinal fluid (n:1). All the study isolates were pure and were not passaged for more than 3 times.

Identification of bacterial isolates and susceptibility testing

The isolates were identified by conventional biochemical methods followed by API-E® (BioMérieux, France). Susceptibilities performed by disc diffusion (Kirby-Bauer) method on Mueller Hinton agar [13] and VITEK2® system (BioMérieux, France) showed resistance against beta-lactams and carbapenems (imipenem/meropenem). Colistin susceptibility was performed using broth micro-dilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines, M07-A10, 2019 [14]. Minimum Inhibitory Concentrations (MIC) were performed in 96-well polystyrene microtitre plates using Cation-Adjusted Mueller Hinton Broth and colistin sulfate powders (Sigma-Aldrich, Inc.) Colistin concentration of 0.03–16.0 µg/ml was used [15]. ATCC E. coli 25922, ATCC P. aeruginosa 27853 and NCTC E. coli 13486 were used as controls. Results were read and interpreted after 16–20 h at 35 °C using colistin cut-offs (≤ 2 µg/ml  =  intermediate;  ≥ 4 µg/ml  =  resistant) for Enterobacteriales [14].

DNA extraction

The selected isolates (n  = 34) were inoculated into Brain heart infusion for 24 h. 1 ml of the broth was used for DNA extraction as per QIA®amp DNA extraction kit (QIAGEN, USA) manufacturer’s protocol. The quality of the extracted DNA was examined using Qubit v.2.0 fluorometer (Life Technologies, USA). The extracted DNA was stored at − 80 °C till further processing.

mcr-1 gene real-time PCR

Real‐time PCR was performed on the extracted DNA in duplicate. 20‐μl reactions were set up containing Platinum® SYBR® Green qPCR Supermix‐UDG (Invitrogen), 150 nm forward and reverse primers and 2 μl of DNA on a BioRad CFX 7500 thermal cycler. Sequence specific primers were used for mcr-1 [16] gene and the house keeping gene rho, [17]. Primer sequences are provided in Additional file 1: Table S1. NCTC 13846 E. coli was used as positive control.

Whole genome sequencing

Eight K. pneumoniae (CRKP1-CRKP6) strains were selected for whole genome sequencing (WGS) with six resistant and two intermediate to colistin. We had clinical data on only 4 isolates: one colistin intermediate isolate failed microbiological clearance for 3 years despite treatment, while three colistin resistant isolates achieved microbiological clearance between 7 and 11 days. DNA was shipped to Eurofins scientific SE, Luxembourg for sequencing. Sequencing was carried out on the Illumina NovaSeq 6000 platform using 2 × 150 Sequence mode. WGS was performed with the genome coverage of 99%. Genetic analysis of reads was done using the KmerGeni tool which generated an approximate of 5.1 Mbp contigs. The de novo assemblies were evaluated by QUAST and Icarus tools. The evaluation was based on the alignment of the de novo assemblies on the reference genome (HS11286). The contigs were annotated with RAST to look for resistance genes.

Data submission

The raw sequences generated after sequencing were submitted to NCBI-SRA website under the accession numbers SAMN16684225–SAMN16684230. This Whole Genome Shotgun project genome assemblies were deposited at DDBJ/ENA/GenBank under the accession JAEMV(N/O/P/Q/R/S)000000000. The version described is JAEMVX010000000. The complete data details are available in the BioProject PRJNA674952.

Data analysis

The raw Illumina reads were passed through quality check using FASTQC and then assembled with SPAdes-3.13.0 software using spade and plasmid spade scripts to generate raw chromosomal and plasmid contigs. The generated assembly quality assessment was conducted using QUAST (http://bioinf.spbau.ru/quast). Continuous chromosome sequence was generated by overlapping raw contigs assembly against the reference genome by abacas.1.3.1 perl script that closed gaps on shotgun assembled contigs against the reference genome based on alignment between assembly and reference to identify syntenies of contigs with the reference. Multi-Locus Sequence Typing (MLST) was determined using K. pneumoniae Sequence Typing web-based tool (PasteurMLST) (https://bigsdb.pasteur.fr/). The MLST was performed using the seven housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) according to the protocol described by Diancourt et al. [18]. RAST server (https://rast.nmpdr.org/) and Center for Genomic Epidemiology server (www.cbs.dtu.dk/services) were used for Chromosomal and Plasmid sequence annotations and downstream analysis.

Phylogenetic analysis

The phylogenetic inference was done by aligning the eight isolates genome with the reference using MegaX software (https://www.megasoftware.net/). The aligned sequences were then converted into a Phylodendogram using the software package Clonal Frame version 1.1. The dendogram was then estimated under the maximum likelihood (ML) principle in PhyloXML (http://www.phyloxml.org/). The tree was colored and edited using FigTree (http://tree.bio.ed.ac.uk/software/figtree/). The tree was further magnified to show closely related genome using SNP (single nucleotide polymorphism) cluster generated by Pathogen detection Browser (https://www.ncbi.nlm.nih.gov/pathogens/isolates/).

Results

mcr-1 gene PCR

A total of 34 colistin resistant K. pneumoniae isolates were included. These strains were investigated for the presence of mcr-1 gene. However, PCR conducted revealed absence of mcr-1 gene in all isolates tested.

Alternate mechanisms involved in colistin resistance

WGS was performed to further understand the mechanism of colistin resistance. Mutations in genes involved in lipid-A and Ara-4 N pathways were revealed through a variant analysis of non-synonymous single nucleotide variants (ns-SNVs Table 1).
Table 1

Lipid A pathways related variants identified in colistin-resistant Klebsiella pneumoniae isolates

IsolatesMICGenBank accessionLipid A modificationLipid A-Ara4N pathway (polymyxin resistance)
PagPPhoRArnA_ DH/FTUgdHArnCArnT
S10.25JAEMVQ000000000.1I189FA424_V425insSerAlaN354DA55G
L65F
S20.5JAEMVP000000000.1I189FA424_V425insSerAlaV17IS10fsA55G
S34JAEMVA000000000I189FL65FT185AA55G
S48JAEMVS000000000.1I189FL65FN354DS10fs
S54JAEMVR000000000.1I189FA424_V425insSerAlaT185AN354DS10fsA55G
L65FS18AS10fs
S616JAEMVO000000000.1I189FA424_V425insSerAlaT185AN354DS10fsA55G
L65FS18A
S716JAEMVN000000000.1I189FA424_V425insSerAlaL260IA376VS10fs
M45ID205NN354D
S8≥ 16JAEMVB000000000I189FL65FV17IA55G

MIC minimal inhibitory concentrations. The table represents various mutations (amino acid) found upon whole genome sequencing analysis of eight Klebsiella pneumonia strains isolated from clinical samples

Lipid A pathways related variants identified in colistin-resistant Klebsiella pneumoniae isolates MIC minimal inhibitory concentrations. The table represents various mutations (amino acid) found upon whole genome sequencing analysis of eight Klebsiella pneumonia strains isolated from clinical samples The mutations detected in PagP gene (I189F) were present in all isolates. In Pho R gene, mutations identified included: A424_V425insSerAla present in all isolates except S3, S4 and S8; L65F present in all isolates except S2 and S7. Additionally, M45I mutation was also identified in isolate S7. Modifications in Lipid A-Ara4N pathway were detected in ArnA_ DH/FT, UgdH, ArnC and ArnT genes. ArnA_ DH/FT included mutations T185A, S18A, L260I and D205N. Mutations detected in UgdH were N354D, V17I, N354D. Mutation detected in ArnC was S10fs and in ArnT was A55G. Mutations in ArnA_ DH/FT gene were detected in S3, S5, S6 and S7 isolates. UgdH gene modification was found in all isolates except S3, mutations in ArnC were present in all except S1, S2 and S8 and ArnT were detected in all except S4 and S7.

Multi locus sequence typing of K. pneumoniae

MLST revealed that the isolates belonged to ST37 (n=1), ST147 (n=3), ST14 (n=1), ST 11 (n=1), ST39 (n=1) and ST 17 (n=1) sequence types (Table 2).
Table 2

The general genetic characteristics of the Klebsiella pneumoniae strains

SamplesNo. of contigsTotal length of assemblyN50GC content (%)Multi-locus sequence typing (MLST)Plasmids namesPercent identity against plasmid
S1995,817,4651,00,46856.6314ColKP3, IncFIB(K), IncFIB(Mar), IncFII, IncHI1B, IncR100, 100, 99, 100, 100, 100
S2535,166,7628,02,57057.3511IncA/C2, IncFIB(pQil), IncFII(K)100, 100, 100
S3875,709,2941,85,63156.96147Col440I, ColRNAI, IncFIB(pQil), IncFII(K), IncL/M(pOXA-48), IncR, IncX496, 96, 96, 97, 100, 100, 100
S4885,699,2231,67,14756.7237ColKP3, FIA(pBK30683), IncFII(K), IncHI1B100, 97, 95, 99
S52545,993,5141,00,46856.63147Col440I, ColKP3,ColRNAI, IncFIB(pKPHS1, IncFIB(pQil), IncFII(K), IncL/M(pOXA-48), IncR, IncX496, 100, 96, 98, 100, 97, 100, 100, 100
S6725,758,6752,98,38256.99147ColRNAI, IncFIB(pQil), IncFII(K), IncL/M(pOXA-48), IncR96,100, 97, 100, 100
S7975,408,1662,59,06157.3339Col440I, IncFIB(pQil), IncFII(K)100, 100, 97
S81225,742,2612,63,70256.9517IncFIB(K), IncFIB(pKPHS1), IncFIB(pQil), IncFII(K), IncX399, 98, 100, 97, 100

No. of contigs number of contiguous data; N50 sequence length at 50%, GC content glycine cystine content; MLST multi-locus sequence typing. The most common MLST sequence strain isolated was ST147 (n  = 3)

The general genetic characteristics of the Klebsiella pneumoniae strains No. of contigs number of contiguous data; N50 sequence length at 50%, GC content glycine cystine content; MLST multi-locus sequence typing. The most common MLST sequence strain isolated was ST147 (n  = 3)

Phylogenetic analysis

The dendrogram was plotted (n = 41,172 as per 6th March 2021) using NCBI Pathogen Detection database (Fig. 1). S3, S5 and S6 (ST147) did not cluster with the reference strain, however, S4 (ST37) was the closest, followed by S2 (ST11) and then S1 (ST14) and S8 (ST17).
Fig. 1

Dendrogram colistin-resistant—Klebsiella pneumoniae isolates, along with magnified sub-clades for S1 and S4 based on SNP cluster was plotted using Pathogen Detection Browser

Dendrogram colistin-resistant—Klebsiella pneumoniae isolates, along with magnified sub-clades for S1 and S4 based on SNP cluster was plotted using Pathogen Detection Browser In addition to the above, clustering with other sequences deposited in the database was also observed. S4 clustered with clinical strain CFSAN059641 isolated in 2020 in Pakistan and also with the other clinical strains deposited (PDT0009285111). S1 clustered with clinical strains isolated in USA (2020), and also with others from Australia, Canada and India (2019).

Discussion

Although novel treatment approaches are being explored [20-23], increasing prevalence of colistin resistant K. pneumoniae, continue to pose a serious global threat. In Pakistan mcr-1 gene has been detected in 23.3% E. coli (n  = 120) and 40% of K. pneumoniae (n  = 60) [24]. Our study however revealed absence of mcr-1 gene in all isolates tested. These findings are consistent with earlier studies also reporting absence of mcr-1 gene in colistin resistant clinical study isolates [25] and suggest presence of factors other than mcr-1 gene contributing to colistin resistance in these isolates. Alternative mechanisms suggested for colistin resistance include: decreased drug permeability by porin loss, resistance to antibiotic penetration through bio-film formation [26] and mutations leading to alteration in antibiotic binding sites and efflux pump [27]. In our isolates WGS showed the modifications in PagP and PhoR genes of lipid A pathway. Mutations in PagP has been shown to be associated with colistin resistance [28, 29]. Also, mutations in the phoB-phoR operon have shown to contribute to the anti-microbial resistance by downregulation of PhoE [30]. Mutations found in genes of Lipid A-Ara4N pathway including Arn_DH/F, ArnC, ArnT have been reported in K. pneumonia [28]. We additionally detected mutations in UgdH gene of Lipid A-Ara4N pathway which has been shown to be implicated in colistin resistance in E. coli [31]. Gram negative bacteria develop resistance against cationic antimicrobial peptides by masking negative charges of the lipid A phosphate substituent through the addition of L-Ara4N positively charged-moieties. Briefly, L-Ara4N is transferred to lipid A by a lipid carrier in a reaction catalysed by ArnT. The synthesis of lipid carrier linked to L-Ara4N is catalyzed by UDP-Glc 6-dehydrogenase (Ugd), ArnA, ArnB, ArnC, and ArnD [32]. This pathway is well-explained in studies in E. coli and S. enterica sv. typhimurium [33]. It is important to note that the mutations found in Lipid A and L-Ara4N pathway were present in all isolates comprising of 6 colistin resistant and 2 colistin intermediate strains. One of our colistin intermediate isolate with mutations in both Lipid A and A-Ara4N pathway, failed to achieve microbiological clearance over 3 years, despite treatment. There is inherent variability in testing methods for colistin susceptibility, hence the susceptible category has been removed by CLSI [14]. Colistin monotherapy is also discouraged to avoid excessive reliance on even the currently recommended broth dilution susceptibility testing method. Hence, learning more about molecular mechanisms of colistin resistance might be helpful for taking clinical decisions in future. The MLST done showed that eight K. pneumoniae isolates belonged to 6 different sequence types (ST11, ST14, ST17, ST37, ST39 and ST147) hence pointing towards the presence of considerable genetic diversity among them. Previous studies have shown that ST11 and ST14 have been detected amongst clinical isolates from Pakistan [25]. Globally, ST11 has been reported in Korea [34], Tunisia [35], and Egypt and linked with the presence of CTX-M gene [3]. ST 14 has been shown to be circulating in Dubai [36], India [37], Pakistan [25] and described to carry NDM-1 and CTX-M [38]. ST 17 are also reported to be mostly extended spectrum beta lactamases (ESBL) carrying clones [39]. ST 147 detected has been shown globally to be linked with resistance [15, 40, 41]. ST37 has been reported with carbapenem resistance and ST39 [42] with ESBLs. This study highlights the significant challenges posed by multi-drug resistant K. pneumoniae strains to global health and emphasizes the need to identify factors contributing to resistance towards their better treatment and control.

Limitations

Although the study highlights mechanism of colistin resistance alternate to mcr-1 gene in clinical isolates in Pakistan, it can be further strengthened by increasing sample size and by performing functional studies to validate the role of mutations found in Lipid A and L-Ara4N pathway in contributing colistin resistance. Additional file 1: Table S1. Primers and probe sequences to target the plasmid-mediated colistin resistance (mcr-1) and housekeeping gene rho. Figure S1. Amplification of mcr-1 gene in a positive control NCTC 13846 E. coli strain. DNA was extracted from the pure culture of NCTC 13846 E. coli strain using DNA extraction kit (Qiagen) as per manufacturers instruction. Extracted DNA was subjected to PCR using sequence specific primers of mcr-1 gene. The figure shows the amplification of mcr-1 gene in the positive control used in the experiment. PC denotes positive control and NTC denotes non-template control.
  40 in total

1.  Tigecycline Susceptibility of Klebsiella pneumoniae Complex and Escherichia coli Isolates from Companion Animals: The Prevalence of Tigecycline-Nonsusceptible K. pneumoniae Complex, Including Internationally Expanding Human Pathogenic Lineages.

Authors:  Toyotaka Sato; Kazuki Harada; Masaru Usui; Yuzo Tsuyuki; Tsukasa Shiraishi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Microb Drug Resist       Date:  2017-12-12       Impact factor: 3.431

2.  Genomic Insights into Colistin-Resistant Klebsiella pneumoniae from a Tunisian Teaching Hospital.

Authors:  Nadia Jaidane; Rémy A Bonnin; Wejdene Mansour; Delphine Girlich; Elodie Creton; Garance Cotellon; Cherifa Chaouch; Noureddine Boujaafar; Olfa Bouallegue; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae.

Authors:  Tony Velkov; Zakuan Z Deris; Johnny X Huang; Mohammad A K Azad; Mark Butler; Sivashangarie Sivanesan; Lisa M Kaminskas; Yao-Da Dong; Ben Boyd; Mark A Baker; Matthew A Cooper; Roger L Nation; Jian Li
Journal:  Innate Immun       Date:  2013-07-25       Impact factor: 2.680

Review 4.  Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance.

Authors:  Shiri Navon-Venezia; Kira Kondratyeva; Alessandra Carattoli
Journal:  FEMS Microbiol Rev       Date:  2017-05-01       Impact factor: 16.408

5.  Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance.

Authors:  Meredith S Wright; Yo Suzuki; Marcus B Jones; Steven H Marshall; Susan D Rudin; David van Duin; Keith Kaye; Michael R Jacobs; Robert A Bonomo; Mark D Adams
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 6.  Resistance to polymyxins: Mechanisms, frequency and treatment options.

Authors:  Matthew E Falagas; Petros I Rafailidis; Dimitrios K Matthaiou
Journal:  Drug Resist Updat       Date:  2010-06-17       Impact factor: 18.500

7.  Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43.

Authors:  Hsin-Yao Cheng; Yi-Fong Chen; Hwei-Ling Peng
Journal:  J Biomed Sci       Date:  2010-07-24       Impact factor: 8.410

8.  Detection of MCR-1 Gene in Multiple Drug Resistant Escherichia coli and Klebsiella pneumoniae in Human Clinical Samples from Peshawar, Pakistan.

Authors:  Fareeha Hameed; Muhammad Asif Khan; Hazrat Bilal; Hafsah Muhammad
Journal:  Comb Chem High Throughput Screen       Date:  2021       Impact factor: 1.339

9.  In-vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modification.

Authors:  Suzanne Bialek-Davenet; Noémie Mayer; Julia Vergalli; Marion Duprilot; Sylvain Brisse; Jean-Marie Pagès; Marie-Hélène Nicolas-Chanoine
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

Review 10.  Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice.

Authors:  Jorge Reyes; Ana Cristina Aguilar; Andrés Caicedo
Journal:  Int J Gen Med       Date:  2019-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.